The graph presents prostate cancer relative survival rates in the U.S. from 2001 to 2016, showing 1-year, 5-year, and 10-year relative survival percentages based on age groups. The x-axis represents age groups, while the y-axis indicates survival rates at different time intervals. Survival rates remain high across all age groups, with patients aged 65–69 having the highest 10-year survival rate of 99.5%. In contrast, men aged 80 and older have the lowest survival rates, with 92.1% at 1 year and 82.7% at 10 years. The data highlights that younger patients generally experience better long-term survival outcomes.

In the period 2018-2019, 2021, it was estimated that U.S. men aged 65 to 84 years and older had a **** percent chance of developing prostate cancer. This statistic shows the probability of males in the United States developing prostate cancer in 2018-2019, 2021, by age.

This statistic shows the number of registrations of newly diagnosed cases of prostate cancer in England in 2022, by age group. Over **** thousand new cases were reported among men aged 70 to 74 years of age in this year.

Legacy unique identifier: P00624

Legacy unique identifier: P00628

In 2023, the projected incidence rate of prostate cancer in the Australian population was around 444 cases per 100,000 in the 75 to 79 age group, an incidence rate higher than any other age group. In contrast, the prostate cancer incidence rate was projected to be below one case per 100,000 amongst the Australian population in age groups less than 39 years.

For 2023, it was estimated that there would be 3,200 new prostate cancer cases among those aged 50 to 59 years in Canada. This statistic displays the estimated number of new prostate cancer cases in Canada among males by age group in 2023.

Prostate cancer incidence rates in the United States vary significantly across racial and ethnic groups, with Non-Hispanic Black men facing the highest risk. According to recent data, Non-Hispanic Black males have an incidence rate of 194.8 per 100,000 population, which is substantially higher than the overall rate of 120.2 per 100,000. This stark disparity highlights the importance of targeted screening and prevention efforts to address this health inequality. Incidence and mortality trends The burden of prostate cancer in the U.S. has grown in recent years. In 2025, approximately 313,780 men were projected to be diagnosed with prostate cancer, representing a significant increase from previous years. Despite this rising incidence, mortality rates have shown improvement. In 2022, the prostate cancer death rate was 18.7 per 100,000 men, compared to a rate of almost 39 per 100,000 in the year 1990. This decrease reflects advancements in treatment and early detection. Risk factors and survival rates Age remains a critical risk factor for prostate cancer, with men aged 65 to 84 having a 10.6 percent chance of developing the disease. However, there is encouraging news regarding survival rates. From 2014 to 2020, the five-year relative survival rate for prostate cancer patients in the U.S. was an impressive 97 percent. This high survival rate underscores the importance of early detection and the effectiveness of current treatment options.

Number and rate of new cancer cases diagnosed annually from 1992 to the most recent diagnosis year available. Included are all invasive cancers and in situ bladder cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

Number of new cases and age-standardized rates of new cancer cases by stage at diagnosis from 2011 to the most recent diagnosis year available. Included are colorectal, lung, breast, cervical and prostate cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

Number and percentage of incident cases of prostate cancer and deaths by age group.

This table contains 600 series, with data for years 1997 - 1997 (not all combinations necessarily have data for all years). This table contains data described by the following dimensions (Not all combinations are available): Geography (15 items: Canada; Prince Edward Island; Newfoundland and Labrador; Nova Scotia ...), Sex (3 items: Both sexes; Females; Males ...), Selected sites of cancer (ICD-9) (4 items: Colorectal cancer; Prostate cancer; Lung cancer; Female breast cancer ...), Characteristics (5 items: Relative survival rate for cancer; High 95% confidence interval; relative survival rate for cancer; Number of cases; Low 95% confidence interval; relative survival rate for cancer ...).

BackgroundProstate cancer in men's health has become a significant driver of global disease burden, impacting aging populations worldwide. This study assesses its prevalence from 1990 to 2021 to reveal ongoing epidemiological trends and inform effective public health strategies.MethodsProstate cancer prevalence estimates, including their 95% uncertainty intervals (UIs), were derived from the Global Burden of Disease (GBD) 2021 study. Then, temporal trends spanning the past 32 years were thoroughly analyzed using Joinpoint regression, with projections for the next 25 years made using the Bayesian Age-Period-Cohort (BAPC) model. Concurrently, disease trends were decomposed into components of population growth, aging, and epidemiological changes. Additionally, age-period-cohort (APC) models were also employed to explore the impact of age, time, and cohort effect on the relative risk of prostate cancer prevalence. And the cross-country inequalities in the prevalence of prostate cancer burden were meticulously evaluated through the Socio-Demographic Index (SDI), revealing significant disparities across socio-economic strata.ResultIn 2021, over 10 million prostate cancer cases were recorded worldwide—a 188.85% increase from 3.6 million in 1990. The age-standardized prevalence rate (ASPR) rose at an estimated annual percentage change of 0.64% (95% UI: 0.47%−0.82%); Joinpoint regression revealed a steady increase in case numbers over 32 years, while the ASPR peaked and then slightly declined. Decomposition analysis showed population growth as the main driver (65.62%), with epidemiological changes and aging accounting for 17.97 and 16.41%, respectively. APC modeling indicated the highest relative risk around age 75—nearly 10 times that of the general population (RR: 9.99; 95% CI: 9.97–10.01). Projections through 2046 forecast a continued rise in both total cases and ASPR.ConclusionsAs a major health concern among older adult men, the global prevalence of prostate cancer has risen steadily since 1990, with population growth identified as the primary driver. Moreover, SDI-related disparities across 204 countries and territories have widened over time. Finally, the APC model forecasts a continuous increase in prevalence over the next 25 years, underscoring the growing disease burden and the urgent need for more targeted and effective management strategies.

At-Home Prostate Cancer Testing Market size was valued at USD 103 Billion in 2023 and is projected to reach USD 196 Billion by 2031, growing at a CAGR of 10.6% during the forecasted period 2024 to 2031.

Global At-Home Prostate Cancer Testing Market Drivers

The market drivers for the At-Home Prostate Cancer Testing Market can be influenced by various factors. These may include:

Raising Awareness: More people are looking at testing possibilities as a result of growing awareness of prostate cancer and the value of early detection. Ease and accessibility: People with busy schedules or mobility challenges may find at-home testing especially appealing as it provides the ease of testing without requiring clinic visits.

Global At-Home Prostate Cancer Testing Market Restraints

Several factors can act as restraints or challenges for the At-Home Prostate Cancer Testing Market. These may include:

Regulatory Obstacles: Tight laws controlling diagnostics and medical equipment might delay the licensing of at-home test kits, which can prevent new players from entering the market.

Limited Awareness: Patients may not be aware of the advantages and accessibility of at-home testing, which can impede uptake. Accuracy Concerns: Before employing at-home tests, potential customers may be hesitant due to doubts regarding their accuracy and dependability in comparison to more conventional testing techniques.

From 2018 to 2022, around 34 percent of prostate cancer deaths in the United States were among men aged 75 to 84 years. During that period, the median age of death for prostate cancer was 79 years. This statistic shows the distribution of prostate cancer deaths in the United States between 2018 and 2022, by age.

In 2023, it was estimated that there would be ** deaths due to prostate cancer among those between 50 and 59 years in Canada. Cancer is one of the leading causes of premature death in Canada. This statistic displays the estimated number of prostate cancer deaths in Canada among males by age group in 2023.

Additional file 2: Table S1. Prostate cancer association results for 269 established PCa risk variants from Conti et al. Table S2. Hazard ratio for PCa associated with a 269-SNP PRS. Table S3. Baseline characteristics for General-, EOPC- and LOPC-group from UK Biobank case–control population. Table S4. Odds ratio for PCa associated with a 269-SNP PRS. Table S5. 2,555 Genome-wide significant variants associated with the risk of PCa in the Cox proportional hazard model in UK Biobank. Table S6. 91 Genome-wide significant variants associated with the risk of EOPC in the Cox proportional hazard model in UK Biobank. Table S7. 2500 Genome-wide significant variants associated with the risk of LOPC in the Cox proportional hazard model in UK Biobank. Table S8. 319 independent variants among 1555 Genome-wide significant variants associated with the risk of PCa based on clumping in 1000 Genomes Project. Table S9. 45 independent variants among 223 Genome-wide significant variants associated with the risk of EOPC based on clumping in 1000 Genomes Project. Table S10. 296 independent variants among 1583 Genome-wide significant variants associated with the risk of LOPC based on clumping in 1000 Genomes Project. Table S11. Hazard ratio for PCa associated with the General-, EOPC- and LOPC-PRS based on UK BioBank follow-up cohort. Table S12. Odds ratio for PCa associated with the General-, EOPC- and LOPC-PRS based on UK BioBank case–control population. Table S13. 397 merged SNPs from the 269-SNP PRS and General-PRS. Table S14. 62 merged SNPs from the 269-SNP PRS and EOPC-PRS. Table S15. 375 merged SNPs from the 269-SNP PRS and LOPC-PRS. Table S16. Hazard ratio for PCa associated with the merged-General-, merged-EOPC- and merged-LOPC-PRS based on UK BioBank follow-up cohort. Table S17. Odds ratio for PCa associated with the merged-General-, merged-EOPC- and merged-LOPC-PRS based on UK BioBank case-comtrol population. Table S18. High-confidence traits linked to PCa through two-sample MR analysis. Table S19. High-confidence traits linked to EOPC through two-sample MR analysis. Table S20. High-confidence traits linked to LOPC through two-sample MR analysis.

As of 2019, the age-standardized prostate cancer prevalence rate was highest among the white male population group with 79.03 recorded incidences per 100,000 population. Colored males followed with 64.47 incidences per 100,000 population in the same year. However, Indian/Asian males had the lowest rate, with 36.43 reported incidences of prostate cancer in 2019.

Number and rate of new cancer cases by stage at diagnosis from 2011 to the most recent diagnosis year available. Included are colorectal, lung, breast, cervical and prostate cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

In 2022, the incidence among the most common cancer types in Germany differed across age groups. Among individuals from the age groups 0 to 44 and 45 to 65 years old, breast cancer had the highest incidence, at 25.6 and 18.5 percent, respectively. Conversely, for those aged 65 and above, prostate cancer had the highest incidence, at 15.6 percent. This statistic depicts the distribution of cancer incidence in Germany in 2022, by cancer type and age group.